Clinical Trial Update: A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD [Phase 4]

View source ↗

Summary

This document reports a 12-month open-label Phase 4 safety study of Aptensio XR in children aged 4-5 years diagnosed with attention-deficit/hyperactivity disord…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• APTENSIO XR (METHYLPHENIDATE HYDROCHLORIDE)

Snippet

Sponsor: Rhodes Pharmaceuticals, L.P. | Conditions: Attention Deficit Disorder With Hyperactivity | Phase 4 | Status: UNKNOWN